Article
Neurosciences
Paolo Solla, Tommaso Ercoli, Carla Masala, Gianni Orofino, Laura Fadda, Davide Giacomo Corda, Ignazio Roberto Zarbo, Mario Meloni, Elia Sechi, Caterina Francesca Bagella, Giovanni Defazio
Summary: This article reports three PD patients who developed a severe withdrawal syndrome after discontinuing the use of rasagiline. The syndrome was characterized by prominent psychiatric disorders and autonomic symptoms, resembling dopamine agonist withdrawal syndrome. This report highlights the importance of closely monitoring PD patients undergoing rasagiline suspension for withdrawal symptoms and provides interesting insights into the role of rasagiline and other MAO-B inhibitors in mood disorders.
Article
Clinical Neurology
David J. Arpin, Trina Mitchell, Derek B. Archer, Roxana G. Burciu, Winston T. Chu, Hanzhi Gao, Thomas Guttuso, Christopher W. Hess, Song Lai, Irene A. Malaty, Nikolaus R. McFarland, Ofer Pasternak, Catherine C. Price, Aparna Wagle Shukla, Samuel S. Wu, Michael S. Okun, David E. Vaillancourt
Summary: The study did not find evidence that 1mg/day of rasagiline has a disease-modifying effect in Parkinson's Disease over 1 year. The free-water accumulation in pSN increased significantly over 1 year, and baseline free-water levels were related to clinical motor progression.
MOVEMENT DISORDERS
(2022)
Article
Clinical Neurology
C. Warren Olanow, Robert A. Hauser, Daniel J. Burdick, Rohit Dhall, Joy Antonelle de Marcaida, Ramon A. Gil, David L. Kreitzman, Lawrence W. Elmer, Andrew Mcgarry, Karl Kieburtz
Summary: This study found that P2B001 was superior to its individual components in treating Parkinson's disease and had comparable efficacy to marketed doses of pramipexole-ER, but with less worsening of sleepiness and fewer dopaminergic adverse events.
MOVEMENT DISORDERS
(2023)
Editorial Material
Medicine, Research & Experimental
Robert A. Hauser, Nir Giladi, Werner Poewe, Jonathan Brotchie, Hadas Friedman, Sheila Oren, Pninit Litman
Summary: Despite the superior efficacy of levodopa in reducing motor symptoms of Parkinson's disease, its risk of inducing motor complications necessitates consideration of alternative treatments. P2B001, a combination of pramipexole and rasagiline, shows potential for greater efficacy and better tolerability compared to other approaches. It also maintains a lower risk of motor complications compared to levodopa.
ADVANCES IN THERAPY
(2022)
Article
Clinical Neurology
Ganqiang Liu, Chunming Ni, Jiamin Zhan, Weimin Li, Junfeng Luo, Zhixiang Liao, Joseph J. Locascio, Wenbiao Xian, Ling Chen, Zhong Pei, Jean-Christophe Corvol, Jodi Maple-Grodem, Meghan C. Campbell, Alexis Elbaz, Suzanne Lesage, Alexis Brice, Albert Y. Hung, Michael A. Schwarzschild, Michael T. Hayes, Anne-Marie Wills, Bernard Ravina, Ira Shoulson, Pille Taba, Sulev Koks, Thomas G. Beach, Florence Cormier-Dequaire, Guido Alves, Ole-Bjorn Tysnes, Joel S. Perlmutter, Peter Heutink, Jacobus J. van Hilten, Roger A. Barker, Caroline H. Williams-Gray, Clemens R. Scherzer
Summary: The study shows that specific mitochondrial haplogroups are associated with the progression of cognitive decline in patients with Parkinson's disease, but not with the progression of motor impairment. This finding suggests that mitochondrial haplotypes may be a useful tool for stratifying patients based on their risk of cognitive decline.
Review
Neurosciences
Domiziana Rinaldi, Marika Alborghetti, Edoardo Bianchini, Michela Sforza, Silvia Galli, Francesco E. Pontieri
Summary: Symptoms of cognitive impairment are common in early stage of Parkinson's disease and may lead to dementia. The worsening of cognitive symptoms depends on the progression of dopaminergic damage and involvement of other neurotransmitter systems in different brain regions. This review focuses on the effects of monoamine-oxidase type B inhibitors on cognition in Parkinson's disease.
CURRENT NEUROPHARMACOLOGY
(2023)
Article
Clinical Neurology
Neil P. Oxtoby, Louise-Ann Leyland, Leon M. Aksman, George E. C. Thomas, Emma L. Bunting, Peter A. Wijeratne, Alexandra L. Young, Angelika Zarkali, Manuela M. X. Tan, Fion D. Bremner, Pearse A. Keane, Huw R. Morris, Anette E. Schrag, Daniel C. Alexander, Rimona S. Weil
Summary: This study estimated the sequence of Parkinson's disease progression in patients at elevated risk for dementia, beginning with classic prodromal features, offering a route to earlier and more precise detection and characterizing variability in the sequence.
Article
Pharmacology & Pharmacy
Daphna Laifenfeld, Chen Yanover, Michal Ozery-Flato, Oded Shaham, Michal Rosen-Zvi, Nirit Lev, Yaara Goldschmidt, Iris Grossman
Summary: Research utilizing real-world healthcare data has identified two drugs with significant beneficial effects on Parkinson's disease progression, providing insights into potential disease-modifying therapeutic solutions.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Neurosciences
Dong-Woo Ryu, Sang-Won Yoo, Yoon-Sang Oh, Kwang-Soo Lee, Seunggyun Ha, Joong- Seok Kim
Summary: According to this study, Parkinson's disease patients can be categorized into brain-predominant PD and PD with body involvement phenotypes based on the onset of cardiac sympathetic denervation (CSD). The study found that PD patients with body involvement had more severe initial symptoms and experienced faster progression of motor deterioration, indicating potentially more severe involvement of the central and peripheral nervous systems.
NEUROBIOLOGY OF DISEASE
(2022)
Article
Neurosciences
Michael C. Brumm, Andrew Siderowf, Tanya Simuni, Elliot Burghardt, Seung Ho Choi, Chelsea Caspell-Garcia, Lana M. Chahine, Brit Mollenhauer, Tatiana Foroud, Douglas Galasko, Kalpana Merchant, Vanessa Arnedo, Samantha J. Hutten, Alyssa N. O'Grady, Kathleen L. Poston, Caroline M. Tanner, Daniel Weintraub, Karl Kieburtz, Kenneth Marek, Christopher S. Coffey
Summary: Clinically relevant milestones in Parkinson's disease occur frequently, even in early stages, and are associated with baseline features but not with symptomatic treatment. Further studies are needed to validate these results and explore their translation into outcome measures for observational and therapeutic studies.
JOURNAL OF PARKINSONS DISEASE
(2023)
Article
Clinical Neurology
F. Stocchi, L. Vacca, P. Grassini, C. Tomino, G. Caminiti, M. Casali, V. D'Antoni, M. Volterrani, M. Torti
Summary: The study demonstrates that overnight switch from rasagiline to safinamide is safe and well tolerated by patients, without causing serotonin syndrome or hypertensive crisis. Short-term substitution of these two drugs did not result in adverse effects on blood pressure in most patients.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Article
Medicine, General & Internal
Ruwei Ou, Qianqian Wei, Yanbing Hou, Lingyu Zhang, Kuncheng Liu, Junyu Lin, Tianmi Yang, Jing Yang, Zheng Jiang, Wei Song, Bei Cao, Huifang Shang
Summary: This study suggests that a shorter reproductive lifespan contributes to faster motor progression in PD female patients, which is important for understanding the role of endogenous estrogen exposure in female PD and for selecting appropriate patients in clinical trials.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Clinical Neurology
Edoardo Bianchini, Michela Sforza, Domiziana Rinaldi, Marika Alborghetti, Lanfranco De Carolis, Francesco Della Gatta, Francesco E. Pontieri
Summary: Switching PD patients from rasagiline to high-dose safinamide may provide more powerful benefits in fluctuating PD patients, significantly reducing subjective symptoms of wearing-off without any reported adverse events.
NEUROLOGICAL RESEARCH
(2021)
Review
Clinical Neurology
Wolfgang H. Jost
Summary: Since the 1980s, MAO-B inhibitors have gained significant status in the treatment of Parkinson's disease, but the neuroprotective effect of these inhibitors has often been misunderstood. Currently, rasagiline, selegiline, and safinamide are commonly used therapeutic options, but they are often not properly appreciated.
JOURNAL OF NEURAL TRANSMISSION
(2022)
Review
Behavioral Sciences
Geir Bjorklund, Massimiliano Peana, Michael Maes, Maryam Dadar, Beatrice Severin
Summary: Redox dysfunctions and neuro-oxidative stress play a major role in the pathophysiology and progression of Parkinson's disease (PD). Lowered GSH metabolism and a low GSH/GSSG ratio following oxidative stress are associated with mitochondrial dysfunctions and neuroinflammatory processes accompanying PD. Antioxidant approaches may have therapeutic efficacy in treating PD and its progression by neutralizing reactive oxygen species.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
(2021)
Article
Clinical Neurology
Jose-Francisco Rocha, Georg Ebersbach, Andrew Lees, Eduardo Tolosa, Joaquim J. Ferreira, Werner Poewe, Olivier Rascol, Fabrizio Stocchi, Angelo Antonini, Diogo Magalhaes, Helena Gama, Patricio Soares-da-Silva
Summary: Opicapone 50mg is well-tolerated in patients with Parkinson's disease and end-of-dose fluctuations, especially in those who are in earlier stages of the disease and levodopa treatment.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Claudio Del Percio, Susanna Lopez, Giuseppe Noce, Roberta Lizio, Federico Tucci, Andrea Soricelli, Raffaele Ferri, Flavio Nobili, Dario Arnaldi, Francesco Fama, Carla Buttinelli, Franco Giubilei, Moira Marizzoni, Bahar Guntekin, Gorsev Yener, Fabrizio Stocchi, Laura Vacca, Giovanni B. Frisoni, Claudio Babiloni
Summary: Abnormalities in rsEEG rhythms can be used to monitor and evaluate the progression of Alzheimer's disease. This study suggests that these abnormalities can be observed using fewer scalp electrodes in patients with mild cognitive impairment due to AD. The findings show that specific bipolar channels exhibit power density changes in ADMCI patients, and these changes can accurately classify ADMCI individuals.
CLINICAL EEG AND NEUROSCIENCE
(2023)
Review
Clinical Neurology
Andrew Lees, Eduardo Tolosa, Fabrizio Stocchi, Joaquim J. Ferreira, Olivier Rascol, Angelo Antonini, Werner Poewe
Summary: There is a resurgence of levodopa as the initial treatment for Parkinson's disease, while the addition of adjuvant treatments is an established strategy to reduce motor complications. Improving levodopa delivery to the brain and combining agents earlier in the disease course can leverage the full potential of this strategy.
EXPERT REVIEW OF NEUROTHERAPEUTICS
(2023)
Article
Geriatrics & Gerontology
Susanna Lopez, Claudio Del Percio, Roberta Lizio, Giuseppe Noce, Alessandro Padovani, Flavio Nobili, Dario Arnaldi, Francesco Fama, Davide V. Moretti, Annachiara Cagnin, Giacomo Koch, Alberto Benussi, Marco Onofrj, Barbara Borroni, Andrea Soricelli, Raffaele Ferri, Carla Buttinelli, Franco Giubilei, Bahar Guntekin, Gorsev Yener, Fabrizio Stocchi, Laura Vacca, Laura Bonanni, Claudio Babiloni
Summary: This study compared the hubs of interdependencies in elderly individuals with and without Alzheimer's disease dementia (ADD) using rsEEG rhythms. The results showed that ADD patients have lower connectivity centrality and directionality compared to normal elderly individuals.
FRONTIERS IN AGING NEUROSCIENCE
(2023)
Article
Clinical Neurology
Giovanni Mostile, Christian Geroin, Roberto Erro, Antonina Luca, Enrico Marcuzzo, Paolo Barone, Roberto Ceravolo, Sonia Mazzucchi, Andrea Pilotto, Alessandro Padovani, Luigi Michele Romito, Roberto Eleopra, Carlo Dallocchio, Carla Arbasino, Francesco Bono, Pietro Antonio Bruno, Benedetta Demartini, Orsola Gambini, Nicola Modugno, Enrica Olivola, Laura Bonanni, Alberto Albanese, Gina Ferrazzano, Rosa De Micco, Maurizio Zibetti, Giovanna Calandra-Buonaura, Martina Petracca, Francesca Morgante, Marcello Esposito, Antonio Pisani, Paolo Manganotti, Fabrizio Stocchi, Mario Coletti Moja, Ilaria Antonella Di Vico, Lucia Tesolin, Francesca De Bertoldi, Tommaso Ercoli, Giovanni Defazio, Mario Zappia, Alessandra Nicoletti, Michele Tinazzi
Summary: This study identified clinical subtypes of combined FMDs using a data-driven approach. Two distinct clusters were identified based on motor phenotype, and their characteristics were described in detail. This study provides valuable insights for further understanding and diagnosing FMD.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Peter A. LeWitt, Fabrizio Stocchi, David Arkadir, Yoseph Caraco, Liat Adar, Itay Perlstein, Ryan Case, Nir Giladi
Summary: Continuous subcutaneous infusion of ND0612 provides stable and sustained plasma concentrations of levodopa, avoiding troughs in levodopa plasma concentrations associated with off time in Parkinson's disease. This delivery system has the potential to be a convenient and well-tolerated option for PD patients experiencing motor fluctuations.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Stuart H. Isaacson, Alyssa Bowling, Ian Zhang, Eric Pappert, Fabrizio Stocchi
Summary: This study evaluated the timing of motor improvement in Parkinson's disease patients with OFF episodes using carbidopa/levodopa (CD/LD) and apomorphine sublingual film (SL-APO). Results showed that mean improvements in MDS-UPDRS-III scores were -6.7 and -16.3 at 15 and 30 minutes following the first daily CD/LD dose, and FULL ON was achieved by 6.5% and 41.8% of patients, respectively. With an optimized SL-APO dose, mean improvements in MDS-UPDRS-III scores were -13.9 and -22.9, and FULL ON was achieved by 34.7% and 81.0% of patients, respectively. In conclusion, concomitant administration of SL-APO with CD/LD may be beneficial for delayed ON.
NEURODEGENERATIVE DISEASE MANAGEMENT
(2023)
Review
Clinical Neurology
Valentina Leta, Lisa Klingelhoefer, Katherine Longardner, Marta Campagnolo, Hafize Cotur Levent, Federico Aureli, Vinod Metta, Roongroj Bhidayasiri, Guy Chung-Faye, Cristian Falup-Pecurariu, Fabrizio Stocchi, Peter Jenner, Tobias Warnecke, K. Ray Chaudhuri
Summary: Levodopa is the gold standard treatment for Parkinson's disease, but it often leads to motor and non-motor fluctuations. Gastrointestinal barriers, such as dysphagia, delayed gastric emptying, and gut dysbiosis, can affect levodopa absorption and response. Managing gastrointestinal dysfunction is crucial for optimizing levodopa therapy.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Review
Clinical Neurology
Stefanie Jost, Marie-Ann Kaldenbach, Angelo Antonini, Pablo Martinez-Martin, Lars Timmermann, Per Odin, Regina Katzenschlager, Rupam Borgohain, Alfonso Fasano, Fabrizio Stocchi, Nobutaka Hattori, Prashanth Lingappa Kukkle, Mayela Rodriguez-Violante, Cristian Falup-Pecurariu, Sebastian Schade, Jan Niklas Petry-Schmelzer, Vinod Metta, Daniel Weintraub, Guenther J. Deuschl, Alberto J. Espay, Eng-King Tan, Roongroj Bhidayasiri, Victor S. C. Fung, Francisco Cardoso, Claudia Trenkwalder, Peter Jenner, K. S. Ray Chaudhuri, Haidar Dafsari
Summary: This study reviewed the investigations on drug therapy for Parkinson's disease since 2010 and proposed a new drug conversion formula. These conversion formulas can help us compare drug regimens across different clinical trials. The results are important for studying the pharmacological efficacy of Parkinson's disease treatments as well as other non-pharmacological interventions.
MOVEMENT DISORDERS
(2023)
Article
Clinical Neurology
Fabrizio Stocchi, Paolo Barone, Giuseppe Bellelli, Andrea Fagiolini, Luigi Ferini Strambi, Sandro Sorbi, Alessandro Padovani
Summary: The diagnosis of depression in Parkinson's disease is challenging due to overlapping symptoms. A panel of Italian specialists reached a consensus that depression is a risk factor for Parkinson's disease, with neuropathological abnormalities playing a role. Multimodal and SSRI antidepressants are confirmed as effective options for treating depression in Parkinson's disease.
NEUROLOGICAL SCIENCES
(2023)
Article
Clinical Neurology
Maria Francesca De Pandis, Margherita Torti, Rossella Rotondo, Lanfranco Iodice, Maria Levi Della Vida, Miriam Casali, Laura Vacca, Fabio Viselli, Valeria Servodidio, Stefania Proietti, Fabrizio Stocchi
Summary: This study evaluated the efficacy of an education program for Parkinson's disease patients. It found that the program significantly improved motor and non-motor symptoms, particularly in reducing daily OFF hours. The long-term efficacy of the program was also confirmed.
FRONTIERS IN NEUROLOGY
(2023)
Review
Clinical Neurology
Manon Auffret, Daniel Weiss, Fabrizio Stocchi, Marc Verin, Wolfgang H. Jost
Summary: Device-aided therapies (DAT), including deep brain stimulation and pump-based continuous dopaminergic stimulation, have significantly improved the clinical management of Parkinson's disease (PD). However, there are disparities in access to DAT, raising concerns about the equal opportunity for advanced PD patients to receive these treatments. Factors such as access to care, referral patterns, physician biases, and patient preferences need to be considered in addressing these disparities.
JOURNAL OF NEURAL TRANSMISSION
(2023)
Article
Clinical Neurology
Alessandro Padovani, Angelo Antonini, Paolo Barone, Giuseppe Bellelli, Andrea Fagiolini, Luigi Ferini Strambi, Sandro Sorbi, Fabrizio Stocchi
Summary: This Delphi study aims to reach a shared point of view among Italian specialists on depression in Alzheimer's disease (AD). Consensus was achieved in most cases (86%), with 80% of statements receiving positive consensus and 6% receiving negative consensus. The study also highlights the strong link between depression and AD, as well as specific features of depression in AD compared to major depressive disorder (MDD).
NEUROLOGICAL SCIENCES
(2023)
Proceedings Paper
Computer Science, Artificial Intelligence
Francesco Fontanella, Sonia Pinelli, Claudio Babiloni, Roberta Lizio, Claudio Del Percio, Susanna Lopez, Giuseppe Noce, Franco Giubilei, Fabrizio Stocchi, Giovanni B. Frisoni, Flavio Nobili, Raffaele Ferri, Tiziana D'Alessandro, Nicole Dalia Cilia, Claudio De Stefano
Summary: Although there is currently no cure for Alzheimer's disease, predicting the cognitive decline of patients at an early stage of the disease can help alleviate its burden. This study used machine learning tools and EEG-based features to predict the cognitive decline of Alzheimer's patients, and found that at least three scores were effective in accurately predicting the decline.
IMAGE ANALYSIS AND PROCESSING, ICIAP 2022, PT I
(2022)
Meeting Abstract
Clinical Neurology
Gennaro Pagano, Stefano Zanigni, Annabelle Monnet, Kirsten I. Taylor, Andrea Hahn, Kenneth Marek, Ron Postuma, Nicola Pavese, Fabrizio Stocchi, Tanya Simuni, Giulia D'Urso, Nathalie Pross, Michael Lindemann, Hanno Svoboda, Paulo Fontoura, Rachelle Doody, Geoffrey A. Kerchner, Azad Bonni, Tania Nikolcheva
MOVEMENT DISORDERS
(2022)